Updated
Lexaria BioscienceLEXX · Healthcare
$4.50+7.91%
Market cap$112M
IndustryBiotechnology
Lexaria Bioscience (LEXX) Revenue breakdown
By product, IP Licensing is the largest at 99% of fiscal 2025 revenue, growing 52% a year over 1 years.
Revenue by product
Fiscal years, as Lexaria Bioscience reports them in its 10-K filings; fiscal 2025 total $705,923.
| Products | 2017 | 2018 | 2019 | 2020 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|
| IP Licensing | — | — | — | — | $457,990 | $696,000 | 99% |
| B2B | — | — | — | — | $5,388 | $9,923 | 1% |
| Other | — | — | — | — | $900 | — | — |
| Licensing revenue | $45,809 | $415,183 | $198,000 | $232,909 | — | — | — |
| Product | $16,866 | $16,967 | $24,282 | $150,993 | — | — | — |
| Freight revenuet | $964 | $1,137 | $328 | $641 | — | — | — |
Questions about Lexaria Bioscience
Where does Lexaria Bioscience make its money?
In fiscal 2025, by product: IP Licensing $696,000, B2B $9,923.
From Lexaria Bioscience's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.